Merck (MRK) And Ridgeback Announce Publication of Phase 3 Study of Molnupiravir

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. TSLA
3. WBD
4. AMD
5. USO
6. META
7. AMC
8. MSFT
9. ACN
10. AMZN

Go back to Merck (MRK) And Ridgeback Announce Publication of Phase 3 Study of Molnupiravir
Merck & Co. (NYSE: MRK) Delayed: 148.78 +1.91 (1.30%)
Previous Close $146.87    52 Week High $65.46 
Open $146.79    52 Week Low $47.97 
Day High $149.19    P/E 101.21 
Day Low $145.60    EPS $1.47 
Volume 1,512,817